ストックスクリーナーアプリを入手
1.7285
0.00%
0.0085
前日終値:
$1.72
開ける：
$1.7
24時間の取引高:
30,745
Relative Volume:
0.19
時価総額：
$95.86M
収益：
-
当期純損益:
$-21.38M
株価収益率:
-4.4321
EPS:
-0.39
ネットキャッシュフロー:
$-25.19M
1週間 パフォーマンス:
+6.83%
1か月 パフォーマンス:
-8.02%
6か月 パフォーマンス:
+112.35%
1年 パフォーマンス:
+34.37%
1日の値動き範囲:
$1.64
$1.7899
1週間の範囲:
$1.53
$1.7899
52週間の値動き範囲:
$0.51
$2.86
Connect Biopharma Holdings Ltd Stock (CNTB) Company Profile
名前
Connect Biopharma Holdings Ltd
セクター
電話
858-727-1040
住所
3580 CARMEL MOUNTAIN ROAD, SUITE 200, SAN DIEGO
CNTB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CNTB
Connect Biopharma Holdings Ltd
|
1.7285 | 95.86M | 0 | -21.38M | -25.19M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
380.00 | 96.56B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.56 | 60.08B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.68 | 61.15B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
711.63 | 44.66B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
328.11 | 36.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Connect Biopharma Holdings Ltd Stock (CNTB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-12 | 開始されました | H.C. Wainwright | Buy |
| 2024-03-04 | 開始されました | H.C. Wainwright | Buy |
| 2021-04-13 | 開始されました | Jefferies | Buy |
| 2021-04-13 | 開始されました | Piper Sandler | Overweight |
| 2021-04-13 | 開始されました | SVB Leerink | Outperform |
Connect Biopharma Holdings Ltd (CNTB) 最新ニュース
Eosinophilic Asthma Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Lanier Biotherapeutics, Bio-Thera Solutions, Kinaset Therapeutics, CSPC ZhongQi Pharma - Barchart.com
Eosinophilic Asthma Pipeline 2025: Therapies, MOA Insights, - openPR.com
FY2025 EPS Estimate for Connect Biopharma Lowered by Analyst - MarketBeat
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Sees Large Drop in Short Interest - MarketBeat
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Short Interest Up 204.8% in August - MarketBeat
Asthma Market to Show Paltry Growth at a CAGR of 1.95% During the Forecast Period (2025-2034) | DelveInsight - Yahoo Finance
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Sees Large Increase in Short Interest - Defense World
Connect Biopharma Announces Poster Presentations of Rademikibart at the European Respiratory Society Congress 2025 - Quiver Quantitative
New Asthma Treatment Data: Connect Biopharma's Rademikibart Shows Impact on FEV1 in Type 2 Asthma Trial - Stock Titan
Connect Biopharma completes termination of its American depositary receipt program and directly lists its ordinary shares on Nasdaq - MarketScreener
Connect Biopharma Ends ADR Program, Moves to Direct Nasdaq Listing; Shares Up Premarket - MarketScreener
Connect Biopharma Completes Termination of its American - GlobeNewswire
Biotech Connect Biopharma Completes Strategic Shift to Direct Nasdaq Listing for U.S. Growth - Stock Titan
Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq - Yahoo Finance
COPD Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Genentech, GlaxoSmithKline, Verona Pharma, Regeneron Pharma, Sanofi, MedImmune, EpiEndo Pharma, Tetherex Pharma - Barchart.com
3 Penny Stocks To Watch With Market Caps Over $100M - simplywall.st
Connect Biopharma (CNTB) Expected to Announce Quarterly Earnings on Friday - Defense World
Connect Biopharma Holdings Limited to Participate in Upcoming Healthcare Conferences - Quiver Quantitative
Clinical-Stage Biotech Connect Biopharma Announces Key September Investor Conference Appearances - Stock Titan
We're Keeping An Eye On Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn Rate - Yahoo Finance
Connect Biopharma (NASDAQ:CNTB) Upgraded to Hold at Wall Street Zen - Defense World
Connect Biopharma Advances Clinical Trials and Nasdaq Listing - AInvest
Connect Biopharma Posts Q2 Revenue Drop - AOL.com
Q3 Earnings Estimate for CNTB Issued By Leerink Partnrs - Defense World
HC Wainwright Cuts Earnings Estimates for Connect Biopharma - Defense World
Nuwellis, Inc. to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - Yahoo Finance
Connect Biopharma Reports Q2 Revenue Drop of 99.2% to $48,000, R&D Spending Increases 65.6% to $8.8mln - AInvest
Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide - Yahoo Finance
Connect Biopharma Holdings Ltd SEC 10-Q Report - TradingView
Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Asthma Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight - openPR.com
Connect Biopharma Holdings Limited shares rise 5.63% after-hours following Jazz Pharmaceuticals' FDA approval of Modeyso. - AInvest
Connect Biopharma Shares Rise on Plan to End ADR Program and Directly List on Nasdaq - MSN
What Makes Connect Biopharma Holdings Limited Sponsored ADR (CNTB) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Research Analysts Set Expectations for CNTB Q2 Earnings - MarketBeat
Connect Biopharma (NASDAQ:CNTB) Upgraded at Northland Capmk - Defense World
Q2 Earnings Estimate for CNTB Issued By Northland Capmk - Defense World
Connect Biopharma Holdings Limited's (NASDAQ:CNTB) Market Cap Rose US$51m Last Week; Private Equity Firms Who Hold 42% Profited and so Did Insiders - 富途牛牛
Connect Biopharma stock rating reiterated as Outperform by Northland - Investing.com Australia
Connect Biopharma appoints Jim Schoeneck to board of directors By Investing.com - Investing.com Nigeria
Connect Biopharma appoints Jim Schoeneck to board of directors - Investing.com Australia
Connect Biopharma appoints James A. Schoeneck to board of directors By Investing.com - Investing.com Nigeria
Northland starts Connect Biopharma at Outperform on chance to define new class - TipRanks
Connect Biopharma stock rises after announcing plan to terminate ADR program - Investing.com
Connect Biopharma to terminate ADR program, list ordinary shares By Investing.com - Investing.com India
Connect Biopharma Holdings Ltd (CNTB) 財務データ
収益
当期純利益
現金流量
EPS
2.42%
大文字化:
|
ボリューム (24 時間):